Exton, PA, United States
Exton, PA, United States

Time filter

Source Type

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.


Patent
Morphotek Inc. | Date: 2016-10-17

The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.


The present invention provides methods and kits for assessing whether a subject is afflicted with an FR-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FR-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FR-expressing cancer, and methods of stratifying a subject with an FR-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FR) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FR in a control sample.


This invention provides antibodies that specifically bind the neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are the antibodies of the invention for use in treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.


Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.


Patent
Morphotek Inc. | Date: 2016-11-08

The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.


Patent
Morphotek Inc. | Date: 2017-06-21

The present invention provides a recombinantly expressed human monoclonal antibody that specifically binds to granulocyte macrophage colony stimulating factor (GM-CSF) wherein said antibody comprises a heavy chain comprising a CDR1 of SEQ ID NO: 46, a CDR2 of SEQ ID NO: 47, and a CDR3 of SEQ ID NO: 48 and a light chain comprising a CDR1 of SEQ ID NO: 49, a CDR2 of SEQ ID NO: 50, and a CDR3 of SEQ ID NO: 51.


Patent
Morphotek Inc. | Date: 2016-06-17

Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (Cys80) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.


Patent
Morphotek Inc. | Date: 2016-07-18

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.


This invention relates to a pharmaceutical composition comprising antibodies that specifcally bind to folate receptor- (FR-), said antibodies comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and a light chain comprising the amino acid sequence comprising a single amino acid substitution relative to SEQ ID NO: 2, wherein said composition of antibodies blocks a biological activity of FR- and induces antibody-dependent cellular cytotoxicity (ADCC) of FR--bearing cells, wherein the binding affinity of said composition of antibodies for FR- is at least that corresponding to a dissociation constant of 1 x 10^(-8) M, and wherein said composition is free of a polypeptide consisting of amino acids 20 to 111 of SEQ ID NO: 24, for use in the treatment of folate receptor--expressing ovarian cancer in a patient.

Loading Morphotek Inc. collaborators
Loading Morphotek Inc. collaborators